Left Ventricular Assist Device and the Current State of the Art: HeartMate 3 at 5 Years

[1]  F. Pagani,et al.  The Society of Thoracic Surgeons Intermacs 2022 Annual Report: Focus on 2018 Heart Transplant Allocation System. , 2022, The Annals of thoracic surgery.

[2]  N. Uriel,et al.  Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. , 2022, JAMA.

[3]  Daphne C. Watkins,et al.  Racial and Sex Inequities in the Use of and Outcomes After Left Ventricular Assist Device Implantation Among Medicare Beneficiaries , 2022, JAMA network open.

[4]  J. Killian,et al.  Development of Advanced Heart Failure: A Population-Based Study , 2022, Circulation. Heart failure.

[5]  N. Uriel,et al.  Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial , 2021, European journal of heart failure.

[6]  J. Cleveland,et al.  Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants , 2021, European Journal of Heart Failure.

[7]  N. Barabino,et al.  Progress in the Development of the Pulsatile CorWave LVAD , 2021 .

[8]  C. Milano,et al.  Characteristics of strokes associated with centrifugal flow left ventricular assist devices , 2021, Scientific Reports.

[9]  H. Adams,et al.  Management of Ischemic Stroke Following Left Ventricular Assist Device. , 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[10]  M. Morshuis,et al.  Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. , 2020, European heart journal.

[11]  G. Haas,et al.  Treatment of gastrointestinal bleeding in left ventricular assist devices: A comprehensive review , 2020, World journal of gastroenterology.

[12]  J. Cleveland,et al.  Evaluation for Heart Transplantation and LVAD Implantation: JACC Council Perspectives. , 2020, Journal of the American College of Cardiology.

[13]  Josef Stehlik,et al.  The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. , 2020, The Annals of thoracic surgery.

[14]  A. Cheung,et al.  American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. , 2020, The Journal of thoracic and cardiovascular surgery.

[15]  N. Desai,et al.  Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults: An INTERMACS Analysis. , 2019, JACC. Heart failure.

[16]  M. Walsh,et al.  A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report , 2019, The New England journal of medicine.

[17]  L. Allen,et al.  Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity , 2018, Circulation. Heart failure.

[18]  Sahil Agrawal,et al.  Thirty-Day Readmissions After Left Ventricular Assist Device Implantation in the United States: Insights From the Nationwide Readmissions Database , 2018, Circulation. Heart failure.

[19]  D. Mozaffarian,et al.  National Trends in Admission and In‐Hospital Mortality of Patients With Heart Failure in the United States (2001–2014) , 2017, Journal of the American Heart Association.

[20]  L. Baddour,et al.  Left Ventricular Assist Device Infections: A Systematic Review , 2017, ASAIO journal.

[21]  J. Rogers,et al.  Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. , 2017, JACC. Heart failure.

[22]  Y. Naka,et al.  Changes in End-Organ Function in Patients With Prolonged Continuous-Flow Left Ventricular Assist Device Support. , 2017, The Annals of thoracic surgery.

[23]  Valluvan Jeevanandam,et al.  Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure , 2017, The New England journal of medicine.

[24]  S. Dunlay,et al.  Abstract 20: Dying With a Left Ventricular Assist Device as Destination Therapy , 2016 .

[25]  A. Leuck.  Left ventricular assist device driveline infections: recent advances and future goals. , 2015, Journal of thoracic disease.

[26]  V. Roger,et al.  Frailty and outcomes after implantation of left ventricular assist device as destination therapy. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  V. Rao,et al.  Quality of life for patients supported on a left ventricular assist device , 2011, Expert review of medical devices.

[28]  Francis D. Pagani,et al.  Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device , 2009, Circulation.

[29]  Stuart Russell,et al.  Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[31]  A B de la Rivière,et al.  Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting? , 2001, Journal of the American College of Cardiology.